Overexpression of NDRG2 can inhibit neuroblastoma cell proliferation through negative regulation by CYR61

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 239-244

  Zhang, Zhi Guo ^a,c   Li, Gang ^a   Feng, Da Yun ^a   Zhang, Jian ^b   Qin, Huai Zhou ^a   Ma, Lian Ting ^c   Gao, Guo Dong ^a   Wu, Lin ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

CYR61; NDRG2; Neuroblastoma; Proliferation

Indexed keywords

CDK4 PROTEIN, HUMAN; COMPLEMENTARY DNA; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLINE; CYR61 PROTEIN, HUMAN; CYSTEINE RICH PROTEIN 61; MESSENGER RNA; NDRG2 PROTEIN, HUMAN; P27 ANTIGEN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL PROLIFERATION; DNA MICROARRAY; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; LENTIVIRINAE; METABOLISM; NEUROBLASTOMA; PLASMID; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYSTEINE-RICH PROTEIN 61; DNA, COMPLEMENTARY; DOWN-REGULATION; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LENTIVIRUS; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMIDS; PROLIFERATING CELL NUCLEAR ANTIGEN; RNA, MESSENGER; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84894096927     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.239     Document Type: Article

References (34)

1. Chien W, Kumagai T, Miller CW, et al (2004). Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem, 279, 53087-96.
2. Choi SC, Yoon SR, Park YP, et al (2007). Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med, 39, 705-14.
3. Deng Y, Yao L, Chau L, et al (2003). N-Myc downstream-regulated gene 2 (NDRG2). inhibits glioblastoma cell proliferation. Int J Cancer, 106, 342-7.
4. Foletta VC, Prior MJ, Stupka N, et al (2009). NDRG2, a novel regulator of myoblast proliferation, is regulated by anabolic and catabolic factors. J Physiol, 587, 1619-34.
5. Jandova J, Beyer TE, Meuillet EJ, Watts GS (2012). The matrix protein CCN1/CYR61 is required for alpha(V). beta(5).-mediated cancer cell migration. Cell Biochem Funct, 30, 687-95
6. Kang K, Jung H, Nam S, Lim JS (2011). NDRG2 Promotes GATA-1 Expression through Regulation of the JAK2/STAT Pathway in PMA-stimulated U937 Cells. Immune Netw, 11, 348-57.
7. Kim A, Kim MJ, Yang Y, et al (2009). Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis, 30, 927-36.
8. Kim JT, Kim JW, Kang YH, et al (2012). NDRG2 and PRA1 interact and synergistically inhibit T-cell factor/beta-catenin signaling. FEBS Lett, 586, 3962-8.
9. Kim YJ, Yoon SY, Kim JT, et al (2009). NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma. Carcinogenesis, 30, 598-605.
10. Kim YJ, Yoon SY, Kim JT, et al (2009). NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells. Int J Cancer, 124, 7-15.
11. Lee DC, Kang YK, Kim WH, et al (2008). Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res, 68, 4210-20.
12. Lee KB, Byun HJ, Park SH, et al (2012). CYR61 controls p53 and NF-kappaB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett, 315, 86-95.
13. Li ZQ, Ding W, Sun SJ, et al (2012). Cyr61/CCN1 is regulated by Wnt/beta-catenin signaling and plays an important role in the progression of hepatocellular carcinoma. PLoS One, 7, e35754.
14. Lorentzen A, Lewinsky RH, Bornholdt J, Vogel LK, Mitchelmore C (2011). Expression profile of the N-myc Downstream Regulated Gene 2 (NDRG2). in human cancers with focus on breast cancer. BMC Cancer, 11, 14-21.
15. Lorentzen A, Vogel LK, Lewinsky RH, et al (2007). Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer, 7, 192-9.
16. Lusis EA, Watson MA, Chicoine MR, et al (2005). Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res, 65, 7121-6.
17. Ma J, Jin H, Wang H, et al (2008). Expression of NDRG2 in clear cell renal cell carcinoma. Biol Pharm Bull, 31, 1316-20.
18. Matthay KK (1995). Neuroblastoma: a clinical challenge and biologic puzzle. CA Cancer J Clin, 45, 179-92.
19. Sabile AA, Arlt MJ, Muff R, et al (2012). Cyr61 expression in Osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice. J Bone Miner Res, 27, 58-67
20. Salic A, Mitchison TJ (2008). A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA, 105, 2415-20.
21. Shi H, Jin H, Chu D, et al (2009). Suppression of N-myc downstream-regulated gene 2 is associated with induction of Myc in colorectal cancer and correlates closely with differentiation. Biol Pharm Bull, 32, 968-75.
22. Shi H, Li N, Li S, et al (2010). Expression of NDRG2 in esophageal squamous cell carcinoma. Cancer Sci, 101, 1292-9.
23. Tong X, O'Kelly J, Xie D, et al (2004). Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway. Oncogene, 23, 4847-55.
24. Tong X, Xie D, O'Kelly J, et al (2001). Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. J Biol Chem, 276, 47709-14.
25. Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R (2002). Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene, 21, 8178-85.
26. Tschan MP, Shan D, Laedrach J, et al (2010). NDRG1/2 expression is inhibited in primary acute myeloid leukemia. Leuk Res, 34, 393-8
27. Xie D, Yin D, Tong X, et al (2004). Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res, 64, 1987-96.
28. Xie D, Yin D, Wang HJ, et al (2004). Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res, 10, 2072-81.
29. Xu C, Zheng J, Zhang H, et al (2012). MSP58 knockdown inhibits the proliferation of esophageal squamous cell carcinoma in vitro and in vivo. Asian Pac J Cancer Prev, 13, 3233-8
30. Yang J, Li Y, Wu L, et al (2010). NDRG2 in rat liver regeneration: role in proliferation and apoptosis. Wound Repair Regen, 18, 524-31.
31. Yang J, Zheng J, Wu L, et al (2011). NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-beta1/Smad pathway and altering the MMP2/TIMP2 ratio in rats. PLoS One, 6, e27710.
32. Yao L, Zhang J, Liu X (2008). NDRG2: a Myc-repressed gene involved in cancer and cell stress. Acta Biochim Biophys Sin, 40, 625-35.
33. Yu Y, Gao Y, Wang H, et al (2008). The matrix protein CCN1 (CYR61). promotes proliferation, migration and tube formation of endothelial progenitor cells. Exp Cell Res, 314, 3198-208.
34. Zhao H, Zhang J, Lu J, et al (2008). Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer, 8, 303-11.